Avalo Therapeutics (AVTX) Cash from Operations (2014 - 2026)
Avalo Therapeutics (AVTX) posted Cash from Operations of 17700000.0 for Q1 2026, down 23.88% on a QoQ basis from 14288000.0 in Q4 2025, and down 87.16% year-over-year from 137882125.21 in Q1 2025.
Avalo Therapeutics (AVTX) Cash from Operations (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Cash from Operations history runs 13 years deep, the most recent figure standing at 17700000.0 for Q1 2026.
- Quarterly Cash from Operations fell 87.16% year-over-year to 17700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 59743000.0 (down 14.21% YoY) and the FY2025 annual result came in at 51500000.0, down 4.98% from the prior year.
- Cash from Operations was 17700000.0 for Q1 2026 at Avalo Therapeutics, down from 14288000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5726000.0 in Q3 2022 and bottomed at 17700000.0 in Q1 2026.
- A 5-year average of 10334529.41 and a median of 11343000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 135.15% — and 2024, when it slumped 443.89%.
- Avalo Therapeutics' Cash from Operations stood at 3940000.0 in 2022, then grew by 29.8% to 2766000.0 in 2023, then slumped by 443.89% to 15044000.0 in 2024, then increased by 5.03% to 14288000.0 in 2025, then decreased by 23.88% to 17700000.0 in 2026.
- Business Quant data shows AVTX's Cash from Operations at 17700000.0 in Q1 2026, 14288000.0 in Q4 2025, and 16412000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -17.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.70 Mn |
| Mar 31, 2026 | -17.70 Mn |
| Dec 31, 2025 | -14.29 Mn |
| Dec 31, 2025 | -14.29 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Jun 30, 2025 | -11.34 Mn |
| Jun 30, 2025 | -11.34 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -16.28 Mn |
| Jun 30, 2024 | -16.28 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Dec 31, 2023 | -2.77 Mn |
| Dec 31, 2023 | -2.77 Mn |